Across TCGA pan-cancer cohorts, RCSD1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RCSD1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RCSD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RCSD1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, LIHC, and SKCM are the cancer types where RCSD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.139	0.626	.010	18	view →
LIHC	OS	Median	All	0.144	0.704	.016	6	view →
SKCM	DFS	Median	II,III,IV	0.927	0.668	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RCSD1 tumor-vs-normal RNA expression · all RCSD1 data types